{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/CLBT/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-18T16:00:10.539Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4722,"canonical_name":"Cellebrite DI Ltd.","cik":"0001854587","uei":null,"lei":null,"duns":null,"ticker":"CLBT"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":54},"count":54,"timeline":[{"ts":"2026-10-09","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Cellebrite DI Ltd. — 2026-10-09","url_slug":"/sec/cik-0001854587/schedule-13g/0000919574-26-006851","accession_number":"0000919574-26-006851","importance":55},{"ts":"2026-09-29","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-09-29","url_slug":"/sec/cik-0001854587/4/0001970748-26-000002","accession_number":"0001970748-26-000002","importance":30},{"ts":"2026-09-29","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-09-29","url_slug":"/sec/cik-0001854587/4/0001971298-26-000003","accession_number":"0001971298-26-000003","importance":30},{"ts":"2026-09-25","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-09-25","url_slug":"/sec/cik-0001854587/4/0001628280-26-063560","accession_number":"0001628280-26-063560","importance":30},{"ts":"2026-09-24","kind":"sec.filing","form_type":"6-K","title":"6-K — Cellebrite DI Ltd. — 2026-09-24","url_slug":"/sec/cik-0001854587/6-k/0001213900-26-103045","accession_number":"0001213900-26-103045","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-09-17","url_slug":"/sec/cik-0001854587/4/0001628280-26-062371","accession_number":"0001628280-26-062371","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-09-17","url_slug":"/sec/cik-0001854587/4/0001628280-26-062373","accession_number":"0001628280-26-062373","importance":30},{"ts":"2026-09-02","kind":"sec.filing","form_type":"6-K","title":"6-K — Cellebrite DI Ltd. — 2026-09-02","url_slug":"/sec/cik-0001854587/6-k/0001213900-26-096800","accession_number":"0001213900-26-096800","importance":30},{"ts":"2026-08-27","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-08-27","url_slug":"/sec/cik-0001854587/4/0001628280-26-059297","accession_number":"0001628280-26-059297","importance":30},{"ts":"2026-08-24","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-08-24","url_slug":"/sec/cik-0001854587/144/0001628280-26-058620","accession_number":"0001628280-26-058620","importance":30},{"ts":"2026-08-24","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-08-24","url_slug":"/sec/cik-0001854587/4/0001628280-26-058632","accession_number":"0001628280-26-058632","importance":30},{"ts":"2026-08-19","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-08-19","url_slug":"/sec/cik-0001854587/144/0001628280-26-057832","accession_number":"0001628280-26-057832","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"6-K","title":"6-K — Cellebrite DI Ltd. — 2026-08-18","url_slug":"/sec/cik-0001854587/6-k/0001213900-26-091208","accession_number":"0001213900-26-091208","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-08-13","url_slug":"/sec/cik-0001854587/4/0001628280-26-056495","accession_number":"0001628280-26-056495","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-08-13","url_slug":"/sec/cik-0001854587/4/0001628280-26-056875","accession_number":"0001628280-26-056875","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"6-K","title":"6-K — Cellebrite DI Ltd. — 2026-08-13","url_slug":"/sec/cik-0001854587/6-k/0001213900-26-088681","accession_number":"0001213900-26-088681","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"6-K","title":"6-K — Cellebrite DI Ltd. — 2026-08-13","url_slug":"/sec/cik-0001854587/6-k/0001213900-26-089065","accession_number":"0001213900-26-089065","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"6-K","title":"6-K — Cellebrite DI Ltd. — 2026-08-13","url_slug":"/sec/cik-0001854587/6-k/0001213900-26-089232","accession_number":"0001213900-26-089232","importance":30},{"ts":"2026-08-12","kind":"sec.insider.s","reporter":"Hogan Thomas E.","title":"Chief Executive Officer","shares":139713,"price_per_share":15.3861,"usd_value":2149638,"security_title":"Ordinary shares, par value NIS 0.00001","importance":37.1496381893},{"ts":"2026-08-12","kind":"sec.insider.s","reporter":"Jewell Marcus","title":"Global Chief Revenue Officer","shares":411,"price_per_share":16.0678,"usd_value":6604,"security_title":"Ordinary shares, par value NIS 0.00001","importance":35.0066038658},{"ts":"2026-08-12","kind":"sec.insider.s","reporter":"GEE DAVID NICHOLAS","title":"Chief Marketing Officer","shares":230,"price_per_share":16.0678,"usd_value":3696,"security_title":"Ordinary shares, par value NIS 0.00001","importance":35.003695594},{"ts":"2026-08-11","kind":"sec.form144","reporter":"THOMAS E. HOGAN","title":"Director, Officer","shares":339484,"usd_value":5397796,"security_title":"Ordinary shares, par value NIS 0.00001","approx_sale_date":"2026-08-12","accession_number":"0001628280-26-055716","importance":41.0795592},{"ts":"2026-08-11","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-08-11","url_slug":"/sec/cik-0001854587/144/0001628280-26-055716","accession_number":"0001628280-26-055716","importance":30},{"ts":"2026-08-11","kind":"sec.insider.a","reporter":"Hogan Thomas E.","title":"Chief Executive Officer","shares":339484,"price_per_share":0,"usd_value":0,"security_title":"Ordinary shares, par value NIS 0.00001","importance":15},{"ts":"2026-08-07","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-08-07","url_slug":"/sec/cik-0001854587/144/0001628280-26-054582","accession_number":"0001628280-26-054582","importance":30},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Barter David","title":"Chief Financial Officer","shares":41734,"price_per_share":16.3756,"usd_value":683419,"security_title":"Ordinary shares, par value NIS 0.00001","importance":35.6834192904},{"ts":"2026-07-07","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-07-07","url_slug":"/sec/cik-0001854587/4/0001628280-26-047426","accession_number":"0001628280-26-047426","importance":30},{"ts":"2026-07-06","kind":"sec.form144","reporter":"David Barter","title":"Officer","shares":93989,"usd_value":1470928,"security_title":"Ordinary shares, par value NIS 0.00001","approx_sale_date":"2026-07-08","accession_number":"0001628280-26-047098","importance":40.2941856},{"ts":"2026-07-06","kind":"sec.form144","reporter":"RONNEN ARMON","title":"Former Officer","shares":29330,"usd_value":481748,"security_title":"Common","approx_sale_date":"2026-07-06","accession_number":"0001950047-26-006858","importance":40.096349636},{"ts":"2026-07-06","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-07-06","url_slug":"/sec/cik-0001854587/144/0001950047-26-006858","accession_number":"0001950047-26-006858","importance":30},{"ts":"2026-07-02","kind":"sec.insider.s","reporter":"Hogan Thomas E.","title":"Chief Executive Officer","shares":103188,"price_per_share":15.7566,"usd_value":1625892,"security_title":"Ordinary shares, par value NIS 0.00001","importance":36.6258920408},{"ts":"2026-07-02","kind":"sec.insider.103188","reporter":"Hogan Thomas E.","title":"Chief Executive Officer","shares":103188,"price_per_share":15.7566,"usd_value":1625892,"security_title":"Ordinary shares, par value NIS 0.00001","importance":16.6258920408},{"ts":"2026-07-01","kind":"sec.form144","reporter":"RONNEN ARMON","title":"Former Officer","shares":43983,"usd_value":677343,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001950047-26-006678","importance":40.13546852},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-07-01","url_slug":"/sec/cik-0001854587/144/0001950047-26-006678","accession_number":"0001950047-26-006678","importance":30},{"ts":"2026-06-30","kind":"sec.form144","reporter":"Thomas E. Hogan","title":"Director and Officer","shares":282905,"usd_value":4011593,"security_title":"Ordinary shares, par value NIS 0.00001","approx_sale_date":"2026-07-02","accession_number":"0001628280-26-046137","importance":40.8023186},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-06-30","url_slug":"/sec/cik-0001854587/144/0001628280-26-046137","accession_number":"0001628280-26-046137","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"RONNEN ARMON","title":"Officer","shares":126264,"usd_value":2000969,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001950047-26-005364","importance":40.400193748},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-06-01","url_slug":"/sec/cik-0001854587/144/0001950047-26-005364","accession_number":"0001950047-26-005364","importance":30},{"ts":"2026-05-21","kind":"sec.form144","reporter":"DAVID GEE","title":"Officer","shares":3430,"usd_value":45962,"security_title":"COMMON","approx_sale_date":"2026-05-21","accession_number":"0001950047-26-004919","importance":40.0091924},{"ts":"2026-05-21","kind":"sec.form144","reporter":"DAVID GEE","title":"OFFICER","shares":2243,"usd_value":30056,"security_title":"Ordinary shares, par value NIS 0.00001","approx_sale_date":"2026-05-21","accession_number":"0001213900-26-060076","importance":40.00601124},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-05-19","url_slug":"/sec/cik-0001854587/4/0001628280-26-036157","accession_number":"0001628280-26-036157","importance":30},{"ts":"2026-05-18","kind":"sec.form144","reporter":"MARCUS JEWELL","title":"OFFICER","shares":12658,"usd_value":164301,"security_title":"Ordinary shares, par value NIS 0.00001","approx_sale_date":"2026-05-18","accession_number":"0001213900-26-058444","importance":40.032860168},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Jewell Marcus","title":"Global Chief Revenue Officer","shares":12658,"price_per_share":12.7711,"usd_value":161657,"security_title":"Ordinary shares, par value NIS 0.00001","importance":35.1616565838},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-05-18","url_slug":"/sec/cik-0001854587/144/0001213900-26-058444","accession_number":"0001213900-26-058444","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-05-14","url_slug":"/sec/cik-0001854587/4/0001628280-26-035084","accession_number":"0001628280-26-035084","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Cellebrite DI Ltd. — 2026-05-14","url_slug":"/sec/cik-0001854587/4/0001628280-26-035091","accession_number":"0001628280-26-035091","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"6-K","title":"6-K — Cellebrite DI Ltd. — 2026-05-14","url_slug":"/sec/cik-0001854587/6-k/0001213900-26-056220","accession_number":"0001213900-26-056220","importance":30},{"ts":"2026-05-12","kind":"sec.form144","reporter":"MARCUS JEWELL","title":"OFFICER","shares":383,"usd_value":4998,"security_title":"Ordinary shares, par value NIS 0.00001","approx_sale_date":"2026-05-12","accession_number":"0001213900-26-055232","importance":40.00099963},{"ts":"2026-05-12","kind":"sec.form144","reporter":"DAVID GEE","title":"OFFICER","shares":228,"usd_value":2975,"security_title":"Ordinary shares, par value NIS 0.00001","approx_sale_date":"2026-05-12","accession_number":"0001213900-26-055223","importance":40.00059508},{"ts":"2026-05-12","kind":"sec.insider.s","reporter":"Jewell Marcus","title":"Global Chief Revenue Officer","shares":383,"price_per_share":13.01,"usd_value":4983,"security_title":"Ordinary shares, par value NIS 0.00001","importance":35.00498283},{"ts":"2026-05-12","kind":"sec.insider.s","reporter":"GEE DAVID NICHOLAS","title":"Chief Marketing Officer","shares":228,"price_per_share":13.01,"usd_value":2966,"security_title":"Ordinary shares, par value NIS 0.00001","importance":35.00296628},{"ts":"2026-05-12","kind":"sec.filing","form_type":"144","title":"144 — GEE DAVID NICHOLAS — 2026-05-12","url_slug":"/sec/cik-0001547134/144/0001213900-26-055223","accession_number":"0001213900-26-055223","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"144","title":"144 — Cellebrite DI Ltd. — 2026-05-12","url_slug":"/sec/cik-0001854587/144/0001213900-26-055232","accession_number":"0001213900-26-055232","importance":30},{"ts":"2026-05-12","kind":"sec.insider.a","reporter":"Ramji Shiven","title":"President Products & Tech","shares":423550,"price_per_share":0,"usd_value":0,"security_title":"Ordinary shares, par value NIS 0.00001","importance":15}]}